Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Romidepsin

FDA-approved product (powder, intravenous), marketed as Istodax, Romidepsin.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Romidepsin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Cutaneous T-cell lymphoma
  • Mature T-cell and NK-cell non-Hodgkin lymphoma
  • Neoplasm
  • T-cell non-Hodgkin lymphoma
  • Unspecified peripheral T-cell lymphoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Histone deacetylase (hdac) inhibitors
FDA pharmacologic class
Histone Deacetylase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae38.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis50.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Romidepsin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-3.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-2.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-4.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-3.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Romidepsin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma

    NCT04639843 · start 2022-11-03

    Registered record
    Registry ID
    NCT04639843
    Conditions
    Adult T-cell Leukemia/Lymphoma; Extranodal NK-/T-cell Lymphoma, Nasal Type; Enteropathy-Associated T-Cell Lymphoma; Monomorphic Epiteliotrophic Intestinal T-cell Lymphoma; Hepatosplenic T-cell Lymphoma
    Interventions
    CC-486 (5-azacitidine); Duvelisib; Romidepsin; Doxorubicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2022-11-03
    Completion
    2022-11-03
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdult T-cell Leukemia/Lymphoma; Extranodal NK-/T-cell Lymphoma, Nasal Type; Enteropathy-Associated T-Cell Lymphoma; Monomorphic Epiteliotrophic Intestinal T-cell Lymphoma +1 more
    InterventionCC-486 (5-azacitidine); Duvelisib; Romidepsin; Doxorubicin
    PhasePhase 1
    Registry statusWithdrawn

  • Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas

    NCT04774068 · start 2021-09-01

    Registered record
    Registry ID
    NCT04774068
    Conditions
    Recurrent Anaplastic Large Cell Lymphoma; Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Recurrent Transformed Mycosis Fungoides; Refractory Anaplastic Large Cell Lymphoma; Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Refractory Transformed Mycosis Fungoides; T-Cell Non-Hodgkin Lymphoma
    Interventions
    Parsaclisib; Romidepsin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-09-01
    Completion
    2024-10-27
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Anaplastic Large Cell Lymphoma; Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Recurrent Transformed Mycosis Fungoides +5 more
    InterventionParsaclisib; Romidepsin
    PhasePhase 1
    Registry statusCompleted

  • Emodepside Phase II Trial for Treatment of Onchocerciasis

    NCT05180461 · start 2021-08-30

    Registered record
    Registry ID
    NCT05180461
    Conditions
    Onchocerciasis
    Interventions
    emodepside; matching placebo of emodepside; ivermectin; matching placebo of ivermectin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2021-08-30
    Completion
    2026-10-02
    Enrolment
    578

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOnchocerciasis
    Interventionemodepside; matching placebo of emodepside; ivermectin; matching placebo of ivermectin
    PhasePhase 2
    Registry statusActive not recruiting

  • Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

    NCT04447027 · start 2020-12-17

    Registered record
    Registry ID
    NCT04447027
    Conditions
    Cutaneous T-Cell Lymphoma; Mature T-cell Malignancies; Peripheral T-Cell Lymphoma; Relapsed/ Refractory T-cell Malignancies
    Interventions
    Romidepsin; Lenalidomide; CC-486 (5-azacitidine); Dexamethasone; EKG; Bone Marrow Aspiration/Biopsy; MRI; Lumbar Puncture; TTE
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-12-17
    Completion
    2025-12-17
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCutaneous T-Cell Lymphoma; Mature T-cell Malignancies; Peripheral T-Cell Lymphoma; Relapsed/ Refractory T-cell Malignancies
    InterventionRomidepsin; Lenalidomide; CC-486 (5-azacitidine); Dexamethasone +5 more
    PhasePhase 1
    Registry statusCompleted

  • Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma

    NCT03770000 · start 2019-03-12

    Registered record
    Registry ID
    NCT03770000
    Conditions
    T Cell Lymphoma
    Interventions
    Tenalisib; Romidepsin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2019-03-12
    Completion
    2021-05-14
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionT Cell Lymphoma
    InterventionTenalisib; Romidepsin
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITL

    NCT03593018 · start 2018-11-09

    Registered record
    Registry ID
    NCT03593018
    Conditions
    Relapsed Angioimmunoblastic T-Cell Lymphoma; Refractory Angioimmunoblastic T-cell Lymphoma
    Interventions
    Oral azacitidine; Romidepsin; Bendamustine; Gemcitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-11-09
    Completion
    2025-08-28
    Enrolment
    86

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed Angioimmunoblastic T-Cell Lymphoma; Refractory Angioimmunoblastic T-cell Lymphoma
    InterventionOral azacitidine; Romidepsin; Bendamustine; Gemcitabine
    PhasePhase 3
    Registry statusCompleted

  • Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL)

    NCT03547700 · start 2018-09-26

    Registered record
    Registry ID
    NCT03547700
    Conditions
    Lymphoma, T-Cell, Peripheral
    Interventions
    Romidepsin; Ixazomib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2018-09-26
    Completion
    2020-08-27
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma, T-Cell, Peripheral
    InterventionRomidepsin; Ixazomib
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma

    NCT03534180 · start 2018-08-21

    Registered record
    Registry ID
    NCT03534180
    Conditions
    Anaplastic Large Cell Lymphoma; Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
    Interventions
    Laboratory Biomarker Analysis; Romidepsin; Venetoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-08-21
    Completion
    2023-07-26
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnaplastic Large Cell Lymphoma; Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
    InterventionLaboratory Biomarker Analysis; Romidepsin; Venetoclax
    PhasePhase 2
    Registry statusCompleted

  • Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma

    NCT03161223 · start 2018-05-30

    Registered record
    Registry ID
    NCT03161223
    Conditions
    Lymphoma, T-Cell
    Interventions
    Durvalumab; Pralatrexate; Romidepsin; 5-Azacitidine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2018-05-30
    Completion
    2023-02
    Enrolment
    148

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma, T-Cell
    InterventionDurvalumab; Pralatrexate; Romidepsin; 5-Azacitidine
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

    NCT03432741 · start 2018-03-27

    Registered record
    Registry ID
    NCT03432741
    Conditions
    Breast Adenocarcinoma; Metastatic Breast Carcinoma; Recurrent Breast Carcinoma; Recurrent Hodgkin Lymphoma; Recurrent Mycosis Fungoides; Recurrent Non-Hodgkin Lymphoma; Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Refractory Breast Carcinoma; Refractory Hodgkin Lymphoma; Refractory Mycosis Fungoides; Refractory Nodal Marginal Zone Lymphoma; Refractory Non-Hodgkin Lymphoma; Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Stage IV Breast Cancer AJCC v6 and v7
    Interventions
    Belinostat; Carfilzomib; Copanlisib Hydrochloride; Daratumumab; Fludeoxyglucose F-18; Gemcitabine Hydrochloride; Laboratory Biomarker Analysis; Nivolumab; Obinutuzumab; Pembrolizumab; Positron Emission Tomography; Rituximab; Romidepsin; Saline; Trastuzumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2018-03-27
    Completion
    2022-10-03
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Adenocarcinoma; Metastatic Breast Carcinoma; Recurrent Breast Carcinoma; Recurrent Hodgkin Lymphoma +10 more
    InterventionBelinostat; Carfilzomib; Copanlisib Hydrochloride; Daratumumab +11 more
    PhasePhase 1
    Registry statusTerminated

  • Romidepsin Maintenance After Allogeneic Stem Cell Transplantation

    NCT02512497 · start 2017-12-08

    Registered record
    Registry ID
    NCT02512497
    Conditions
    Cutaneous T-cell Lymphoma; T-Prolymphocytic Leukemia; T-Large Granulocytic Leukemia; T-Lymphoblastic Leukemia/Lymphoma; Peripheral T-Cell Lymphoma
    Interventions
    Romidepsin; Busulfan; Fludarabine; Stem Cell Transplant; Thymoglobulin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-12-08
    Completion
    2025-06-18
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCutaneous T-cell Lymphoma; T-Prolymphocytic Leukemia; T-Large Granulocytic Leukemia; T-Lymphoblastic Leukemia/Lymphoma +1 more
    InterventionRomidepsin; Busulfan; Fludarabine; Stem Cell Transplant +1 more
    PhasePhase 1
    Registry statusCompleted

  • A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma

    NCT02616965 · start 2017-02-22

    Registered record
    Registry ID
    NCT02616965
    Conditions
    Cutaneous T-cell Lymphoma (CTCL)
    Interventions
    Romidepsin; Brentuximab vedotin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-02-22
    Completion
    2024-01-31
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCutaneous T-cell Lymphoma (CTCL)
    InterventionRomidepsin; Brentuximab vedotin
    PhasePhase 1
    Registry statusCompleted

  • Early Administration of Romidepsin and 3BNC117 in Treatment-naïve HIV Patients Starting ART

    NCT03041012 · start 2017-01-20

    Registered record
    Registry ID
    NCT03041012
    Conditions
    Hiv
    Interventions
    Romidepsin; 3BNC117; Antiretrovirals
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-01-20
    Completion
    2022-12-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHiv
    InterventionRomidepsin; 3BNC117; Antiretrovirals
    PhasePhase 2
    Registry statusCompleted

  • Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL

    NCT02757248 · start 2016-11

    Registered record
    Registry ID
    NCT02757248
    Conditions
    PTCL; CTCL
    Interventions
    Volasertib; Romidepsin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2016-11
    Completion
    2016-11
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPTCL; CTCL
    InterventionVolasertib; Romidepsin
    PhasePhase 1
    Registry statusWithdrawn

  • Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas

    NCT02783625 · start 2016-05-23

    Registered record
    Registry ID
    NCT02783625
    Conditions
    Lymphoma; Relapsed/Refractory T-cell Lymphomas
    Interventions
    Romidepsin; Bortezomib; duvelisib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-05-23
    Completion
    2026-04-21
    Enrolment
    114

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma; Relapsed/Refractory T-cell Lymphomas
    InterventionRomidepsin; Bortezomib; duvelisib
    PhasePhase 1
    Registry statusCompleted